{"id":751822,"date":"2023-04-26T19:56:08","date_gmt":"2023-04-26T23:56:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/"},"modified":"2023-04-26T19:56:08","modified_gmt":"2023-04-26T23:56:08","slug":"tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/","title":{"rendered":"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BRISBANE, Calif., April  26, 2023  (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class<sup>1<\/sup> therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2\/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.<\/p>\n<p align=\"justify\">Presentation details:<\/p>\n<p align=\"justify\">\n        <strong>Title:<\/strong>\u00a0A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors<br \/><strong>Session Title:<\/strong>\u00a0Developmental Therapeutics \u2014 Molecularly Targeted Agents and Tumor Biology<br \/><strong>Session Date and Time:<\/strong>\u00a0Saturday, June 3, 2023; 8:00 a.m. \u2013 11:00 a.m. ET <br \/><strong>Abstract Number:<\/strong>\u00a03107<\/p>\n<p align=\"justify\">The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6oeW9sGpmpJR_tQl3_j0acY3VscnmjOc_9hV_sPeQQYAlh1tm_hZMug48pheu7sBqMzjivVZXQG1HfGDMeuxCdPGucUqKYliS9ZaauW2Ek5pwuBZe1o0_izTZyhtK4oTb8YhCAXlOammJW3lC_UgYnVW76JsEjnitggm3EN_LX3uGcRs8gs9XU8uCy2tQhZp\" rel=\"nofollow noopener\" target=\"_blank\">meetings.asco.org<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Tempest Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company\u2019s two novel clinical programs TPST-1120 and TPST-1495, target of PPAR\u03b1 and EP2\/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS\/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uvn_33mw5Rh-Dp2sXa-qpvfquZFPwTVbR5GwEQFntCIEEo0UpctmCas6LghQabRxGHmeSbPB0L7-gRLH4I4Vtw==\" rel=\"nofollow noopener\" target=\"_blank\">www.tempesttx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contacts:<\/strong><br \/>\n        <br \/>Sylvia Wheeler<br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vhixO1J5pN7PgPEfg5HcyKx5LQgon8PWcq-k6NO2fxjXOm2wpHjv7FPC7VkID9i4Sr7EhROv8zHG-BfFmgti6el9gkkpuKzYMFpfZA0P96CY-Z-BMpazU60ZKunCQc3o\" rel=\"nofollow noopener\" target=\"_blank\"><u>swheeler@wheelhouselsa.com<\/u><\/a><\/p>\n<p>Aljanae Reynolds <br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fPT1cGzw5ITaWZu8cd6hq5VlYwglXrgkxUtoPkAkmP09VVtaRvyUGnNS_79xYFrs5NSRP8R5Jv_huZn9P3koX3wsRD3GQXySR-eFiMWd-9woElYcsBbt2VS74WkdFaw7\" rel=\"nofollow noopener\" target=\"_blank\">areynolds@wheelhouselsa.com<\/a><\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup> If approved by the FDA<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmJlYzUwZjAtMmRmMC00NDY0LTljMGEtOTFkYzYzN2I5MzhhLTEyMDE0ODc=\/tiny\/Tempest-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2\/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title:\u00a0A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumorsSession Title:\u00a0Developmental Therapeutics \u2014 Molecularly Targeted Agents and Tumor BiologySession Date and Time:\u00a0Saturday, June 3, 2023; 8:00 a.m. \u2013 11:00 a.m. ET Abstract Number:\u00a03107 The abstract will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751822","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2\/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title:\u00a0A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumorsSession Title:\u00a0Developmental Therapeutics \u2014 Molecularly Targeted Agents and Tumor BiologySession Date and Time:\u00a0Saturday, June 3, 2023; 8:00 a.m. \u2013 11:00 a.m. ET Abstract Number:\u00a03107 The abstract will &hellip; Continue reading &quot;Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T23:56:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting\",\"datePublished\":\"2023-04-26T23:56:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/\",\"name\":\"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=\",\"datePublished\":\"2023-04-26T23:56:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting - Market Newsdesk","og_description":"BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2\/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL. Presentation details: Title:\u00a0A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumorsSession Title:\u00a0Developmental Therapeutics \u2014 Molecularly Targeted Agents and Tumor BiologySession Date and Time:\u00a0Saturday, June 3, 2023; 8:00 a.m. \u2013 11:00 a.m. ET Abstract Number:\u00a03107 The abstract will &hellip; Continue reading \"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T23:56:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting","datePublished":"2023-04-26T23:56:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/","name":"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=","datePublished":"2023-04-26T23:56:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjY2MyM1NTYwMDc3IzIxODk5MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-announces-tpst-1495-poster-presentation-at-the-2023-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tempest Announces TPST-1495 Poster Presentation at the\u00a02023 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751822"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751822\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}